NEURORESTORE Trademark

Trademark Overview

On Tuesday, June 5, 2018, a trademark application was filed for NEURORESTORE with the United States Patent and Trademark Office. The USPTO has given the NEURORESTORE trademark a serial number of 87948788. The federal status of this trademark filing is REGISTERED as of Tuesday, October 26, 2021. This trademark is owned by AlzeCure Pharma AB. The NEURORESTORE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Development of pharmaceutical substances for treatment and easement of Alzheimer's disease, only for human use; Scientific and technological services, namely, conducting early evaluations in the field of new pharmaceuticals, pharmaceutical drug development services, pharmaceutical product evaluation and pharmaceutical research and development; scientific research and design, namely, scientific research in the field of pharmaceuticals; Research in relation to pharmaceuticals; Research and development of vaccines and medicines; Conducting early stage evaluations in the field of new pharmaceuticals; Pharmaceutical drug development services; Drug discovery services; Technical data analysis services, namely, data analysis through data mining; Computer-supported technical analysis services, namely, chemical analysis, and data analysis through data mining
neurorestore

General Information

Serial Number87948788
Word MarkNEURORESTORE
Filing DateTuesday, June 5, 2018
Status700 - REGISTERED
Status DateTuesday, October 26, 2021
Registration Number6540155
Registration DateTuesday, October 26, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 14, 2020

Trademark Statements

Goods and ServicesDevelopment of pharmaceutical substances for treatment and easement of Alzheimer's disease, only for human use; Scientific and technological services, namely, conducting early evaluations in the field of new pharmaceuticals, pharmaceutical drug development services, pharmaceutical product evaluation and pharmaceutical research and development; scientific research and design, namely, scientific research in the field of pharmaceuticals; Research in relation to pharmaceuticals; Research and development of vaccines and medicines; Conducting early stage evaluations in the field of new pharmaceuticals; Pharmaceutical drug development services; Drug discovery services; Technical data analysis services, namely, data analysis through data mining; Computer-supported technical analysis services, namely, chemical analysis, and data analysis through data mining

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, June 11, 2018
Primary Code042
First Use Anywhere DateSaturday, October 31, 2020
First Use In Commerce DateSaturday, October 31, 2020

Trademark Owner History

Party NameAlzeCure Pharma AB
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressHUDDINGE 14157
SE
Party NameAlzeCure Pharma AB
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressHUDDINGE 14157
SE
Party NameAlzeCure Pharma AB
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressHUDDINGE 14157
SE

Trademark Events

Event DateEvent Description
Tuesday, October 26, 2021REGISTERED-PRINCIPAL REGISTER
Saturday, September 18, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, September 17, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, September 15, 2021STATEMENT OF USE PROCESSING COMPLETE
Tuesday, September 7, 2021USE AMENDMENT FILED
Wednesday, September 15, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 7, 2021TEAS STATEMENT OF USE RECEIVED
Wednesday, July 28, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 28, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 28, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 5, 2021EXTENSION 1 GRANTED
Friday, March 5, 2021EXTENSION 1 FILED
Friday, March 5, 2021TEAS EXTENSION RECEIVED
Tuesday, September 8, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 14, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 14, 2020PUBLISHED FOR OPPOSITION
Wednesday, June 24, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 9, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 27, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, April 27, 2020LETTER OF SUSPENSION E-MAILED
Monday, April 27, 2020SUSPENSION LETTER WRITTEN
Tuesday, April 7, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 7, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 2, 2020TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, October 2, 2019NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Wednesday, October 2, 2019INQUIRY TO SUSPENSION E-MAILED
Wednesday, October 2, 2019SUSPENSION INQUIRY WRITTEN
Friday, September 27, 2019SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Tuesday, September 24, 2019ASSIGNED TO LIE
Wednesday, February 27, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, February 27, 2019LETTER OF SUSPENSION E-MAILED
Wednesday, February 27, 2019SUSPENSION LETTER WRITTEN
Saturday, February 23, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 22, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 22, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 22, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 22, 2018NON-FINAL ACTION E-MAILED
Wednesday, August 22, 2018NON-FINAL ACTION WRITTEN
Thursday, August 16, 2018ASSIGNED TO EXAMINER
Monday, June 11, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, June 8, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

neurorestore services research development data analysis pharmaceutical namely pharmaceuticals drug field